Ceptaris Therapeutics

About:

Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.

Website: http://www.ceptaris.com

Top Investors: BioAdvance, Ben Franklin Technology Partners of Southeastern Pennsylvania, Third Point Ventures, Silicon Valley Bank, Vivo Capital

Description:

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.